Decibel Therapeutics Company
Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technology and our expertise in inner ear biology. We are leveraging our platform to advance our pipeline of preclinical gene therapy programs that are designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders.
Total Funding:
189.2M
Headquarters:
Cambridge, Massachusetts, United States
Funding Status:
IPO
Employee Number:
51-100
Estimated Revenue:
$10M to $50M
Last Funding Type:
Series D
Number Of Exists:
51-100
Technology:
Other
Investor Type:
IPO
Last Funding Date:
2020
Investors Number:
16
Founded Date:
2015
Industry:
Biotechnology, Gene therapy, Medical Device, Therapeutics